Nyxoah (NASDAQ:NYXH) Posts Quarterly Earnings Results, Misses Estimates By $0.20 EPS

by · The Cerbat Gem

Nyxoah (NASDAQ:NYXH – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.20), Zacks reports. The firm had revenue of $8.76 million during the quarter, compared to the consensus estimate of $8.64 million. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%.

Here are the key takeaways from Nyxoah’s conference call:

  • U.S. commercialization accelerated: Q2 worldwide revenue rose 21% sequentially to €7.7 million, including 22% U.S. growth to €5.2 million. Active U.S. accounts doubled to 180, while 427 patients were under prior authorization entering Q3, up 77% sequentially.
  • Reimbursement support strengthened: CMS proposed 2027 reimbursement increases of approximately 12% for hospital outpatient facilities and 15% for ambulatory surgery centers for Genio procedures. Nyxoah also reported a 100% prior-authorization approval rate across commercial, Medicare Advantage, and WISeR-submitted Medicare patients.
  • Balance sheet improved materially: The company secured $110 million through a $95 million equity raise and a $15 million EIB loan drawdown, providing funding to expand its U.S. sales organization and patient-funnel initiatives.
  • Full-year guidance was maintained: Nyxoah continues to expect 2026 revenue of €36 million–€40 million and gross margin of 60%–62%, with U.S. revenue expected to grow sequentially in both Q3 and Q4 while international revenue remains broadly stable.
  • Operating expenses remain elevated: Q2 operating expenses increased to €25.1 million, including higher selling, general and administrative costs from the U.S. commercial build-out, while the company reported a €20.6 million operating loss. Full-year operating-expense guidance increased by €1 million to €99 million–€102 million due to a one-time share-based compensation charge.

Nyxoah Trading Up 12.2%

NYXH traded up $0.16 during midday trading on Friday, reaching $1.47. 82,956 shares of the company were exchanged, compared to its average volume of 143,354. The stock has a market capitalization of $56.98 million, a P/E ratio of -0.58 and a beta of 1.62. Nyxoah has a one year low of $1.26 and a one year high of $8.59. The stock’s 50-day simple moving average is $1.66 and its 200 day simple moving average is $2.95. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 2.38.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NYXH. Wall Street Zen raised shares of Nyxoah to a “hold” rating in a research note on Saturday, August 1st. Piper Sandler reissued an “overweight” rating and set a $6.00 price target (down from $7.00) on shares of Nyxoah in a research note on Thursday. Robert W. Baird set a $2.31 price objective on shares of Nyxoah in a report on Thursday. Weiss Ratings cut shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. Finally, Oppenheimer set a $4.00 price objective on shares of Nyxoah in a research note on Thursday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Nyxoah presently has an average rating of “Hold” and an average target price of $5.26.

Check Out Our Latest Stock Analysis on Nyxoah

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. grew its holdings in Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after purchasing an additional 3,353 shares during the period. Bank of America Corp DE boosted its position in shares of Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Nyxoah in the 3rd quarter valued at $98,000. Deutsche Bank AG increased its position in shares of Nyxoah by 40.0% in the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after buying an additional 10,000 shares in the last quarter. Finally, Shay Capital LLC acquired a new stake in Nyxoah during the 2nd quarter worth $374,000.

Nyxoah Company Profile

(Get Free Report)

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.

Featured Stories